Results 31 to 40 of about 22,201 (271)

Contraception Practices Among Women on Opioid Agonist Therapy [PDF]

Journal of Obstetrics and Gynaecology Canada, 2021
Despite increased public awareness and use of opioid agonist therapy (OAT), there is little published data on contraception among women on methadone or buprenorphine/naloxone. This study aimed to characterize patterns of contraception use among this population.We conducted a cross-sectional survey between May 2014 and October 2015 at 6 medical clinics,
Lingsa Jia, Wendy V. Norman
openaire   +3 more sources

Importance of Opioid Agonist Therapy to Reduce Injection-Related Infections. [PDF]

Open Forum Infect Dis, 2022
Weaver VK, Kennedy MC.
europepmc   +3 more sources

Intranasal Oxytocin for Stimulant Use Disorder Among Male Veterans Enrolled in an Opioid Treatment Program: A Randomized Controlled Trial

Frontiers in Psychiatry, 2022
The increasing prevalence of illicit stimulant use among those in opioid treatment programs poses a significant risk to public health, stimulant users have the lowest rate of retention and poorest outcomes among those in addiction treatment, and current ...
Christopher S. Stauffer, Christopher S. Stauffer, Christopher S. Stauffer, Salem Samson, Alex Hickok, Alex Hickok, William F. Hoffman, William F. Hoffman, Steven L. Batki   +8 more
doaj   +1 more source

Personal viewpoint on opioid agonist therapy and transplantation [PDF]

American Journal of Transplantation, 2018
Opioid use disorder (OUD) is an increasing public health problem. Transplant centers worldwide are being confronted with increasing numbers of patients with opioid use disorder and end stage organ disease. Opioid agonist therapy (OAT; ie, methadone, buprenorphine, and buprenorphine/naloxone) is a scientifically proven, effective, physician-prescribed ...
Ana, Ivkovic, Sarah, Wakeman
openaire   +2 more sources

First-line opioid agonist treatment as prevention against assisting others in initiating injection drug use: A longitudinal cohort study of people who inject drugs in Vancouver, Canada

Drug and Alcohol Dependence Reports, 2023
Background: Among people who inject drugs, frequent injecting and experiencing withdrawal are associated with facilitating others’ first injections. As these factors may reflect an underlying substance use disorder, we investigated whether first-line ...
Zachary Bouck, Andrea C. Tricco, Laura C. Rosella, Hailey R. Banack, Matthew P. Fox, Robert W. Platt, M-J Milloy, Kora DeBeck, Kanna Hayashi, Dan Werb   +9 more
doaj   +1 more source

The Affordable Care Act and Opioid Agonist Therapy for Opioid Use Disorder [PDF]

Psychiatric Services, 2019
The study examined whether the use of opioid agonist therapy (OAT) for treatment of opioid use disorder in specialty substance use treatment settings increased following Medicaid expansion.Administrative data on 943,430 admissions from the Treatment Episodes Data Set-Admissions (2010-2016) were used to examine the association between Medicaid expansion
Ramin, Mojtabai, Christine, Mauro, Melanie M, Wall, Colleen L, Barry, Mark, Olfson   +4 more
openaire   +2 more sources

Integrated Nicotine Replacement and Behavioral Support to Reduce Smoking in Opioid Agonist Therapy: A Randomized Clinical Trial.

JAMA Psychiatry
Importance: Approximately 85% of individuals receiving opioid agonist therapy for opioid dependence smoke tobacco. Despite the significant health risks associated with smoking-related diseases, there has been limited evaluation of smoking interventions ...
Druckrey-Fiskaaen KT, Madebo T, Daltveit JT, Vold JH, Furulund E, Chalabianloo F, Gilje Lid T, Fadnes LT.   +7 more
europepmc   +2 more sources

Substances used and OAT (Opioid agonist therapy).

, 2022
Substances used and OAT (Opioid agonist therapy).
Mitchell Levine (445928), Sarah van Gaalen (12436936), Dale Kalina (12436933), Aidan Reid Findlater (12436939), Mark Loeb (248712), Elizabeth Alvarez (4908070), Marek Smieja (117473), Sureka Pavalagantharajah (12436924), Anna Cvetkovic (10670541), Jacqueline Lim (4238824), Eric Lentz (12436930), Lawrence Mbuagbaw (117465), Carol Bassim (12436942), Cynthia Lokker (3813832), Jean-Eric Tarride (201689), Tim O’Shea (8283081), Chris P Verschoor (12436927), Robin Lennox (8314125)   +17 more
core   +1 more source

Treatment retention in opioid agonist therapy: comparison of methadone versus buprenorphine/naloxone by analysis of daily-witnessed dispensed medication in a Canadian Province

BMC Psychiatry, 2022
Background The last decade has shown a remarkable increase in the rates of illicit opioid use in Canada and internationally, which is associated with large increases in opioid related morbidity and mortality.
Joseph Sadek, Joseph Saunders
doaj   +1 more source

A qualitative study on people with opioid use disorders’ perspectives on smoking and smoking cessation interventions

Frontiers in Psychiatry, 2023
IntroductionSmoking-related diseases are major contributors to disability and shorter life expectancy among opioid-dependent patients. Smoking prevalence is considerably higher for opioid-dependent persons than among the general population, and only a ...
Karl Trygve Druckrey-Fiskaaen, Karl Trygve Druckrey-Fiskaaen, Einar Furulund, Einar Furulund, Einar Furulund, Tesfaye Madebo, Tesfaye Madebo, Siv-Elin Leirvåg Carlsen, Lars T. Fadnes, Lars T. Fadnes, Torgeir Gilje Lid, Torgeir Gilje Lid, for ATLAS4LAR Study Group, Vibeke Bråthen Buljovcic, Jan Tore Daltveit, Karl Trygve Druckrey-Fiskaaen, Lars T. Fadnes, Trude Fondenes, Per Gundersen, Beate Haga Trettenes, Siv-Elin Leirvåg Carlsen, Mette Hegland Nordbotn, Maria Olsvold, Marianne Cook Pierron, Christine Sundal, Jørn Henrik Vold, Maren Borsheim Bergsaker, Eivin Dahl, Tone Lise Eielsen, Torhild Fiskå, Marianne Larssen, Torgeir Gilje Lid, Eirik Holder, Tesfaye Madebo, Ewa Joanna Wilk, Mari Thoresen Soot   +35 more
doaj   +1 more source